TY - JOUR
T1 - Role of the BCR complex in B cell development, activation, and leukemic transformation
AU - Rheingold, Susan R.
AU - Brown, Valerie I.
AU - Fang, Junjie
AU - Kim, Jenny M.
AU - Grupp, Stephan A.
N1 - Funding Information:
Supported by NIH 5-T32-CA-09615 (SR, JMK), NIH-T32-HL-07150 (VB), American Society of Clinical Oncology Young Investigator Award (SR, JMK), NIH K-K12-CA-76931 (JMK, VB), NIH R01 CA82156 (SAG), and NIH 1R29A140111 (SAG).
PY - 2003
Y1 - 2003
N2 - A primary focus of signal transduction in B cells, from the pre-B cell to the mature B cell, is the B cell receptor complex. Here we describe work demonstrating the importance of signaling via the pre-B cell receptor complex (pre-BCR) to the pre-B cell transition, the central checkpoint in B-cell development. We have shown tht pre-BCR complex components Igα and Igβ are critical to allowing the pre-B cell to move through this transition, but may not be required for allelic exclusion. Pre-BCR expression also directly affects the response of leukemic cells to steroid treatment, suggesting that signals initiated by the pre-BCR complex may present therapeutic targets in acute leukemia. Additionally, interleukin-7 may also modulate the response of leukemic cells arising from early B-cell stages to treatment. This observation has lead directly to proposals to test drugs which may antagonize early B-cell growth signals, such as rapamycin, in acute lymphoid leukemia.
AB - A primary focus of signal transduction in B cells, from the pre-B cell to the mature B cell, is the B cell receptor complex. Here we describe work demonstrating the importance of signaling via the pre-B cell receptor complex (pre-BCR) to the pre-B cell transition, the central checkpoint in B-cell development. We have shown tht pre-BCR complex components Igα and Igβ are critical to allowing the pre-B cell to move through this transition, but may not be required for allelic exclusion. Pre-BCR expression also directly affects the response of leukemic cells to steroid treatment, suggesting that signals initiated by the pre-BCR complex may present therapeutic targets in acute leukemia. Additionally, interleukin-7 may also modulate the response of leukemic cells arising from early B-cell stages to treatment. This observation has lead directly to proposals to test drugs which may antagonize early B-cell growth signals, such as rapamycin, in acute lymphoid leukemia.
UR - http://www.scopus.com/inward/record.url?scp=0042510077&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042510077&partnerID=8YFLogxK
U2 - 10.1385/IR:27:2-3:309
DO - 10.1385/IR:27:2-3:309
M3 - Review article
C2 - 12857978
AN - SCOPUS:0042510077
SN - 0257-277X
VL - 27
SP - 309
EP - 329
JO - Immunologic Research
JF - Immunologic Research
IS - 2-3
ER -